Viking Therapeutics, Inc. (VKTX)
33.23
-0.66
(-1.95%)
USD |
NASDAQ |
Aug 24, 16:00
33.55
+0.32
(+0.96%)
After-Hours: 05:49
Viking Therapeutics Enterprise Value : 3.379B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 3.379B |
| August 21, 2026 | 3.456B |
| August 20, 2026 | 3.511B |
| August 19, 2026 | 3.700B |
| August 18, 2026 | 3.395B |
| August 17, 2026 | 3.425B |
| August 14, 2026 | 3.374B |
| August 13, 2026 | 3.345B |
| August 12, 2026 | 3.471B |
| August 11, 2026 | 3.445B |
| August 10, 2026 | 3.520B |
| August 07, 2026 | 3.499B |
| August 06, 2026 | 3.387B |
| August 05, 2026 | 3.411B |
| August 04, 2026 | 3.345B |
| August 03, 2026 | 3.306B |
| July 31, 2026 | 3.205B |
| July 30, 2026 | 3.365B |
| July 29, 2026 | 3.402B |
| July 28, 2026 | 3.452B |
| July 27, 2026 | 3.570B |
| July 24, 2026 | 3.561B |
| July 23, 2026 | 3.631B |
| July 22, 2026 | 3.855B |
| July 21, 2026 | 3.929B |
| Date | Value |
|---|---|
| July 20, 2026 | 3.746B |
| July 17, 2026 | 3.828B |
| July 16, 2026 | 3.745B |
| July 15, 2026 | 3.913B |
| July 14, 2026 | 3.932B |
| July 13, 2026 | 3.949B |
| July 10, 2026 | 4.036B |
| July 09, 2026 | 4.302B |
| July 08, 2026 | 4.164B |
| July 07, 2026 | 4.417B |
| July 06, 2026 | 4.018B |
| July 02, 2026 | 3.870B |
| July 01, 2026 | 3.875B |
| June 30, 2026 | 4.053B |
| June 29, 2026 | 3.979B |
| June 26, 2026 | 3.806B |
| June 25, 2026 | 3.684B |
| June 24, 2026 | 3.786B |
| June 23, 2026 | 3.431B |
| June 22, 2026 | 3.149B |
| June 18, 2026 | 2.918B |
| June 17, 2026 | 2.907B |
| June 16, 2026 | 2.833B |
| June 15, 2026 | 2.831B |
| June 12, 2026 | 2.729B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 132.85B |
| Eli Lilly & Co. | 1.220T |
| Regeneron Pharmaceuticals, Inc. | 80.37B |
| Skye Bioscience, Inc. | -0.3526M |
| Eledon Pharmaceuticals, Inc. | 226.57M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -128.02M |
| Total Expenses (Quarterly) | 128.02M |
| EPS Diluted (Quarterly) | -1.101 |
| Earnings Yield | -14.03% |
| Normalized Earnings Yield | -14.03 |